Scott Eggener, MD, University of Chicago Medicine, describes the Stockholm3 test and its purpose in prostate cancer, reasons for validating it in an ethnically-diverse population, the clinical implications of its nearly 3-times superior specificity to PSA, and what is necessary for Stockholm3 to be used in common practice in the United States.
SEPTA: Validation of Stockholm3 in a Multi-Ethnic Cohort for Prostate Cancer Detection
By Scott Eggener, MD - Last Updated: January 30, 2024Related Posts
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.